Literature DB >> 16684875

Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.

Michelle D Roth-Cline1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16684875     DOI: 10.1161/CIRCULATIONAHA.105.604512

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  3 in total

1.  Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.

Authors:  Domenico Motola; Antonio Vargiu; Roberto Leone; Anita Conforti; Ugo Moretti; Alberto Vaccheri; Giampaolo Velo; Nicola Montanaro
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

2.  Should benefit-risk assessment have its own drug "label"?

Authors:  R Scott Braithwaite
Journal:  Drug Healthc Patient Saf       Date:  2011-08-03

3.  Modelling of mouse experimental colitis by global property screens: a holistic approach to assess drug effects in inflammatory bowel disease.

Authors:  Johan Gottfries; Silvia Melgar; Erik Michaëlsson
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.